Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JW Pharmaceutical Corp.

www.cwp.co.kr/pharma/ko/main.jsp

Latest From JW Pharmaceutical Corp.

Deals Shaping The Medical Industry, November 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.

Deals Market Intelligence

JW To Progress Dendritic Cell Therapeutics After Fund Raising

South Korea's JW Group is accelerating efforts to develop cancer immune cell therapies by raising a total of KRW50bn ($42.9m), with the funds to be used for its novel drug development arm JW CreaGene, which has a number of innovative dendritic cell-based candidates in the pipeline.

BioPharmaceutical Asia Pacific

Hanmi’s Licensing Success Driven By Strong Clinical Strategy

Hanmi Pharm's recent record license agreements with multinational pharma giants clearly show that the company may be a step or two ahead of its South Korean rivals in R&D and also indicate its strength in oncology. A local brokerage notes its clinical development strategy may also have played a role in this success and suggests ways other domestic pharmas can reduce failures.

BioPharmaceutical South Korea

Korea Chooses New Group Of Innovators For R&D Support

South Korea’s Ministry of Health and Welfare has unveiled a list of companies that will be designated as innovative pharma firms for the next three years and thus eligible to receive financial and tax incentives to boost their R&D activities.

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Choongwae Pharma Corp.
  • Choongwae Pharma Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • JW Pharmaceutical Corp.
  • Senior Management
  • Lee Chong-Ho, Chmn. & CEO
  • Contact Info
  • JW Pharmaceutical Corp.
    Phone: (82) 2 840 6777
    2477, Nambusunhwan-ro
    Seocho-gu
    Seoul, 137-864
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register